EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
11
05
2021
accepted:
05
08
2021
revised:
03
08
2021
pubmed:
21
8
2021
medline:
14
6
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Transrectal prostate biopsy (TRUSBx) holds a risk of prostate biopsy related sepsis. We discuss our step-wise strategies aiming to reduce this risk, including targeted antimicrobials and switching to a freehand transperineal approach (FHTPBx). This longitudinal cohort study included three groups. Group A underwent TRUSBx with empirical augmented antimicrobial prophylaxis; Group B underwent TRUSBx with targeted antimicrobial prophylaxis, based on rectal-swab cultures/sensitivity; Group C underwent FHTPBx with empirical antimicrobial prophylaxis. Post biopsy sepsis, defined according to the surviving sepsis campaign and confirmed with blood or urinary cultures, were determined and rates between groups were analysed using fisher's exact test. Of all 1501 patients, 23 developed post biopsy sepsis; Group A (12/609, 2.0%), B (9/403, 2.2%), C (2/489, 0.4%). Targeted antimicrobials did not reduce the risk of post biopsy sepsis following TRUSBx (A vs B, 2.0% vs 2.2%; p = 0.82). Patients with antimicrobial-resistant rectal flora had an increased post biopsy sepsis rate following TRUSBx despite targeted antimicrobials (9.1% vs 1.1%, p = 0.003). Switching to FHTPBx reduced the risk of developing post biopsy sepsis (A vs C, 2% vs 0.4%, p = 0.03; B vs C, 2.2% vs 0.4%, p = 0.03). Targeted antimicrobials based on rectal swab culture failed to reduce the overall risk of post biopsy sepsis, while FHTPBx nearly eliminated this risk. We recommend the use of transperineal prostate biopsies for all patients as the most effective method to reduce the risk of sepsis.
Sections du résumé
BACKGROUND
Transrectal prostate biopsy (TRUSBx) holds a risk of prostate biopsy related sepsis. We discuss our step-wise strategies aiming to reduce this risk, including targeted antimicrobials and switching to a freehand transperineal approach (FHTPBx).
SUBJECTS AND METHODS
This longitudinal cohort study included three groups. Group A underwent TRUSBx with empirical augmented antimicrobial prophylaxis; Group B underwent TRUSBx with targeted antimicrobial prophylaxis, based on rectal-swab cultures/sensitivity; Group C underwent FHTPBx with empirical antimicrobial prophylaxis. Post biopsy sepsis, defined according to the surviving sepsis campaign and confirmed with blood or urinary cultures, were determined and rates between groups were analysed using fisher's exact test.
RESULTS
Of all 1501 patients, 23 developed post biopsy sepsis; Group A (12/609, 2.0%), B (9/403, 2.2%), C (2/489, 0.4%). Targeted antimicrobials did not reduce the risk of post biopsy sepsis following TRUSBx (A vs B, 2.0% vs 2.2%; p = 0.82). Patients with antimicrobial-resistant rectal flora had an increased post biopsy sepsis rate following TRUSBx despite targeted antimicrobials (9.1% vs 1.1%, p = 0.003). Switching to FHTPBx reduced the risk of developing post biopsy sepsis (A vs C, 2% vs 0.4%, p = 0.03; B vs C, 2.2% vs 0.4%, p = 0.03).
CONCLUSIONS
Targeted antimicrobials based on rectal swab culture failed to reduce the overall risk of post biopsy sepsis, while FHTPBx nearly eliminated this risk. We recommend the use of transperineal prostate biopsies for all patients as the most effective method to reduce the risk of sepsis.
Identifiants
pubmed: 34413481
doi: 10.1038/s41391-021-00438-w
pii: 10.1038/s41391-021-00438-w
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-287Informations de copyright
© 2021. Crown.
Références
Siegel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
doi: 10.3322/caac.21387
Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–4.
doi: 10.1016/j.eururo.2011.12.058
B Batura D, Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrobial Chemother. 2012;68:247–9.
doi: 10.1093/jac/dks401
Hadjipavlou M, Eragat M, Kenny C, Pantelidou M, Mulhem W, Wood C, et al. Effect of augmented antimicrobial prophylaxis and rectal swab culture–guided targeted prophylaxis on the risk of sepsis following transrectal prostate biopsy. Eur Urol Focus. 2020;6:95–101.
doi: 10.1016/j.euf.2018.06.016
Walker JT, Singla N, Roehrborn CG. Reducing infectious complications following transrectal ultrasound-guided prostate biopsy: a systematic review. Rev Urol. 2021;18:73–89.
doi: 10.1038/s41585-020-00405-5
Wagenlehner F, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the global prevalence study of infections in urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013;63:521–7.
doi: 10.1016/j.eururo.2012.06.003
Vyas L, Acher P, Kinsella J, Challacombe B, Chang R, Sturch P, et al. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. BJU Int. 2014;114:32–7.
doi: 10.1111/bju.12282
Kum F, Elhage O, Maliyil J, Wong K, Faure Walker N, Kulkarni M, et al. Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting. BJU Int. 2019;125:244–52.
doi: 10.1111/bju.14620
Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving sepsis campaign. Crit Care Med. 2013;41:580–637.
doi: 10.1097/CCM.0b013e31827e83af
Susceptibility Testing. British Society for Antimicrobial Chemotherapy. 2021. http://bsac.org.uk/susceptibility/ .
Kuru T, Wadhwa K, Chang R, Echeverria L, Roethke M, Polson A, et al. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics. BJU Int. 2013;112:568–77.
doi: 10.1111/bju.12132
Grummet J, Gorin M, Popert R, O’Brien T, Lamb A, Hadaschik B, et al. “TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis. 2020;23:62–5.
doi: 10.1038/s41391-020-0204-8
EAU guidelines: prostate cancer. Uroweb. 2021. https://uroweb.org/guideline/prostate-cancer/#5 .
Sheehan S, Philpott-Howard J, Wang W, Nemade H, Thompson P. Prospective study assessing the presence of endotoxaemia in patients undergoing transrectal prostate biopsy. J Urol. 2013;189:e474–5.
Opal S. Endotoxins and other sepsis triggers. Contrib Nephrol. 2010;167:14–24.
Tamhankar A, El‐Taji O, Vasdev N, Foley C, Popert R, Adshead J. The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008–2019. BJU Int. 2020;126:133–41.
doi: 10.1111/bju.15062
Berry B, Parry M, Sujenthiran A, Nossiter J, Cowling T, Aggarwal A, et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population‐based study. BJU Int. 2020;126:97–103.
doi: 10.1111/bju.15039
Duplessis C, Bavaro M, Simons M, Marguet C, Santomauro M, Auge B, et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology. 2012;79:556–63.
doi: 10.1016/j.urology.2011.09.057
Taylor A, Zembower T, Nadler R, Scheetz M, Cashy J, Bowen D, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol. 2012;187:1275–9.
doi: 10.1016/j.juro.2011.11.115
Jiang P, Liss M, Szabo R. Targeted antimicrobial prophylaxis does not always prevent sepsis after transrectal prostate biopsy. J Urol. 2018;200:361–8.
doi: 10.1016/j.juro.2018.03.078
Fluoroquinolone antimicrobials: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. GOV.UK. 2021. https://www.gov.uk/drug-safety-update/fluoroquinolone-antimicrobials-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects .
Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013;81:1142–6.
doi: 10.1016/j.urology.2013.02.019
Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801.
doi: 10.1001/jama.2016.0287